Dulaglutide

Generic Name: Dulaglutide

Brand Names: Trulicity

Drug Type: Biotech

CAS Number: 923950-08-7

Unique Ingredient Identifier: WTT295HSY5

Background: Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.

Indication: Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Clinical Trials

A Study of HS-20094 in Patients With T2DM

Phase 2

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: HS-20094
Drug: Dulaglutide
Drug: Palcebo

First Posted Date: 2025-03-30

Last Posted Date: 2025-03-30

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 270

Registration Number: NCT06901648

Locations: 🇨🇳
Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital), Tianjin, Tianjin, China

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial

Phase 4

Not yet recruiting

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Metformin
Drug: Dulaglutide
Drug: Semaglutide 1.0 mg
Drug: Empagliflozin (BI 10773)
Drug: Canagliflozin
Drug: Dapagliflozin
Drug: pioglitazone
Drug: Sitagliptin
Drug: Vildagliptin (Galvus)
Drug: linagliptin

First Posted Date: 2025-02-28

Last Posted Date: 2025-03-04

Lead Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Target Recruit Count: 504

Registration Number: NCT06851962

Locations: 🇪🇸
Hospital Universitario Regional de Málaga, Málaga, Spain
🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸
Hospital General Universitario de Valencia (HGUV), Valencia, Spain

and more 1 locations

Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-17

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 50000

Registration Number: NCT06779929

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Phase 3

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Dulaglutide

First Posted Date: 2024-12-18

Last Posted Date: 2025-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 55

Registration Number: NCT06739122

Locations: 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸
Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States

and more 27 locations